COMBINATION OF AN AGONIST ANTI-PD-1 ANTIBODY WITH A GNRH AGONIST OR ANTAGONIST TO TREAT CANCER

摘要

The present disclosure relates to a novel method of treatment of a cancer patient in which the patient is subjected to both an inhibitor of an immune check point molecule, preferably "Programmed Death 1 " (PD-1) or its ligand "programmed death ligand 1" (PD-L1), and a Gonadotropin-Releasing Hormone (GnRH, also known as LHRH or FSH-RH) agonist or antagonist.